<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466661</url>
  </required_header>
  <id_info>
    <org_study_id>HR#16928</org_study_id>
    <nct_id>NCT00466661</nct_id>
  </id_info>
  <brief_title>Acamprosate vs. Placebo in Bipolar Alcoholics</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Trial of Acamprosate in Alcohol-Dependent Individuals With Comorbid Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To conduct a double-blind, randomized, placebo-controlled outpatient clinical trial of
      acamprosate in individuals with alcohol dependence and bipolar disorder who are also
      receiving mood stabilizing medication. The study will assess the safety and efficacy of
      acamprosate in alcohol-dependent bipolar patients as measured by its effects on alcohol use
      and mood symptoms relative to placebo.

      The primary hypothesis to be tested is whether individuals with comorbid bipolar disorder and
      alcohol dependence who receive acamprosate plus mood stabilizer will have greater improvement
      in alcohol-related outcomes than those who receive mood stabilizer alone. A secondary
      hypothesis that will be explored is that alcohol-dependent bipolar individuals treated with
      acamprosate will have greater mood stability as compared to those treated with mood
      stabilizers alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Drink (Days)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of days after randomization until consumption of first alcoholic beverage per self-report.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Days Abstinent</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of days in trial with no alcohol consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Heavy Drinking Days</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of drinking days that are heavy drinking days (5 or more standard drinks/day for males, 4 or more standard drinks/day for females)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Carbohydrate-deficient Transferrin</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured level of validated serum alcohol biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyltransferase</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measured levels of validated serum alcohol biomarker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obsessive Compulsive Drinking Scale Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Higher scores indicate worse outcome; minimum score = 0, maximum score = 40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>MADRS scores at study endpoint. Higher scores indicate a worse outcome. Minimum score = 0, maximum score = 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>YMRS scores at study endpoint. Higher scores indicate a worse outcome. Minimum score = 0, maximum score = 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Higher values indicate worse outcomes; minimum value = 1, maximum value = 7</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Alcohol Dependence</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Acamprosate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>666 mg p.o. TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acamprosate</intervention_name>
    <description>666 mg po TID</description>
    <arm_group_label>Acamprosate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 tabs po TID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults ages 18-65

          2. Meet DSM-IV criteria for current (past 90 days) alcohol dependence

          3. Meet DSM-IV criteria for bipolar I or bipolar II disorder

          4. Currently on a mood stabilizing medication regimen, including the use of lithium,
             valproic acid, lamotrigine, carbamazepine, and/or antipsychotic agent FDA approved to
             treat bipolar disorder without any dosage adjustments in the past 30 days

          5. Must be able to remain free from alcohol for at least 3 days prior to medication
             initiation

          6. Subjects must be able to adequately provide informed consent and function at an
             intellectual level sufficient to allow the accurate completion of all assessment
             instruments

          7. Subjects must consent to random assignment and be willing to commit to medication
             treatment and follow-up assessments

        Exclusion Criteria:

          1. Individuals with a primary psychiatric disorder other than bipolar disorder

          2. Individuals with an uncontrolled neurologic condition that could confound the results
             of the study

          3. Individuals with an uncontrolled medical condition that may adversely affect the
             conduct of this trial or jeopardize the subject's safety

          4. Participants with creatinine clearance less than or equal to half of normal value as
             indicated by chem. 7 results conducted at screening visit.

          5. Concomitant use of other psychotropic medications not allowed per the protocol

          6. Women of childbearing potential who are pregnant, lactating or refuse to use adequate
             forms of birth control

          7. Current suicidal or homicidal risk

          8. Baseline scores of &gt; 35 on the Montgomery Asberg Depression Rating Scale and/or &gt; 25
             on the Young Mania Rating Scale
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan K Tolliver, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Clinical Neuroscience, Department of Psychiatry, Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen T Brady, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Division of Clinical Neuroscience, Department of Psychiatry, Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Psychiatry, Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <results_first_submitted>October 10, 2018</results_first_submitted>
  <results_first_submitted_qc>December 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2018</results_first_posted>
  <last_update_submitted>December 12, 2018</last_update_submitted>
  <last_update_submitted_qc>December 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acamprosate</keyword>
  <keyword>Alcoholism</keyword>
  <keyword>Bipolar disorder</keyword>
  <keyword>Comorbidity</keyword>
  <keyword>Craving</keyword>
  <keyword>Depression</keyword>
  <keyword>GABA</keyword>
  <keyword>Glutamate</keyword>
  <keyword>Mania</keyword>
  <keyword>Pharmacotherapy</keyword>
  <keyword>Withdrawal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment by clinical referral</recruitment_details>
      <pre_assignment_details>Two week lead-in (Screening, Baseline)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acamprosate</title>
          <description>666 mg p.o. TID</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>At Least 1 Postrandomization Visit</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acamprosate</title>
          <description>666 mg p.o. TID</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.8" spread="6.7"/>
                    <measurement group_id="B2" value="43.7" spread="11.3"/>
                    <measurement group_id="B3" value="42.1" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Drink (Days)</title>
        <description>Number of days after randomization until consumption of first alcoholic beverage per self-report.</description>
        <time_frame>8 weeks</time_frame>
        <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Participants assigned to acamprosate with at least one return visit after randomization</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants assigned to placebo who returned for at least one visit after randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Drink (Days)</title>
          <description>Number of days after randomization until consumption of first alcoholic beverage per self-report.</description>
          <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="6" upper_limit="NA">The upper range of the confidence interval was calculated to be infinity</measurement>
                    <measurement group_id="O2" value="8.0" lower_limit="2.0" upper_limit="NA">The upper range of the confidence interval was calculated to be infinity</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Days Abstinent</title>
        <description>Percentage of days in trial with no alcohol consumption</description>
        <time_frame>8 weeks</time_frame>
        <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Participants assigned to acamprosate with at least one return visit after randomization</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants assigned to placebo who returned for at least one visit after randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Days Abstinent</title>
          <description>Percentage of days in trial with no alcohol consumption</description>
          <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
          <units>percentage of days in trial</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" spread="28.2"/>
                    <measurement group_id="O2" value="73.0" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Heavy Drinking Days</title>
        <description>Percentage of drinking days that are heavy drinking days (5 or more standard drinks/day for males, 4 or more standard drinks/day for females)</description>
        <time_frame>8 weeks</time_frame>
        <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Participants assigned to acamprosate with at least one return visit after randomization</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants assigned to placebo who returned for at least one visit after randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Heavy Drinking Days</title>
          <description>Percentage of drinking days that are heavy drinking days (5 or more standard drinks/day for males, 4 or more standard drinks/day for females)</description>
          <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
          <units>percentage of days drinking</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="8.4"/>
                    <measurement group_id="O2" value="10.7" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Carbohydrate-deficient Transferrin</title>
        <description>Measured level of validated serum alcohol biomarker</description>
        <time_frame>8 weeks</time_frame>
        <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Participants assigned to acamprosate with at least one return visit after randomization</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants assigned to placebo who returned for at least one visit after randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Carbohydrate-deficient Transferrin</title>
          <description>Measured level of validated serum alcohol biomarker</description>
          <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
          <units>&quot;percent CDT&quot;</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.8"/>
                    <measurement group_id="O2" value="2.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gamma-glutamyltransferase</title>
        <description>Measured levels of validated serum alcohol biomarker</description>
        <time_frame>8 weeks</time_frame>
        <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Participants assigned to acamprosate with at least one return visit after randomization</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants assigned to placebo who returned for at least one visit after randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Gamma-glutamyltransferase</title>
          <description>Measured levels of validated serum alcohol biomarker</description>
          <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
          <units>Gamma-glutamyltransferase U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="40.0"/>
                    <measurement group_id="O2" value="63.8" spread="67.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Obsessive Compulsive Drinking Scale Score</title>
        <description>Higher scores indicate worse outcome; minimum score = 0, maximum score = 40</description>
        <time_frame>8 weeks</time_frame>
        <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Participants assigned to acamprosate with at least one return visit after randomization</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants assigned to placebo who returned for at least one visit after randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Obsessive Compulsive Drinking Scale Score</title>
          <description>Higher scores indicate worse outcome; minimum score = 0, maximum score = 40</description>
          <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="9.5"/>
                    <measurement group_id="O2" value="15.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montgomery Asberg Depression Rating Scale Score</title>
        <description>MADRS scores at study endpoint. Higher scores indicate a worse outcome. Minimum score = 0, maximum score = 60.</description>
        <time_frame>8 weeks</time_frame>
        <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Participants assigned to acamprosate with at least one return visit after randomization</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants assigned to placebo who returned for at least one visit after randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale Score</title>
          <description>MADRS scores at study endpoint. Higher scores indicate a worse outcome. Minimum score = 0, maximum score = 60.</description>
          <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" spread="6.5"/>
                    <measurement group_id="O2" value="11.3" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Young Mania Rating Scale Score</title>
        <description>YMRS scores at study endpoint. Higher scores indicate a worse outcome. Minimum score = 0, maximum score = 60.</description>
        <time_frame>8 weeks</time_frame>
        <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Participants assigned to acamprosate with at least one return visit after randomization</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants assigned to placebo who returned for at least one visit after randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Young Mania Rating Scale Score</title>
          <description>YMRS scores at study endpoint. Higher scores indicate a worse outcome. Minimum score = 0, maximum score = 60.</description>
          <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="2.9"/>
                    <measurement group_id="O2" value="5.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression Scale Score</title>
        <description>Higher values indicate worse outcomes; minimum value = 1, maximum value = 7</description>
        <time_frame>8 weeks</time_frame>
        <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>Participants assigned to acamprosate with at least one return visit after randomization</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants assigned to placebo who returned for at least one visit after randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression Scale Score</title>
          <description>Higher values indicate worse outcomes; minimum value = 1, maximum value = 7</description>
          <population>Sample analyzed is a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30).</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.4"/>
                    <measurement group_id="O2" value="3.7" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>Known adverse events and or serious adverse events are reported for a modified intention to treat (mITT) sample of all randomized subjects who returned for at least one visit post-randomization (total mITT n=30). Adverse event data (all-cause mortality, serious adverse events, all other adverse events) could not be obtained in randomized participants lost to follow-up (n=3).</desc>
      <group_list>
        <group group_id="E1">
          <title>Acamprosate</title>
          <description>Participants assigned to acamprosate</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants assigned to placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactoid skin reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diffuse aches</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limited sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bryan K. Tolliver, M.D., Ph.D. (Principal Investigator)</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>(843) 792-4869</phone>
      <email>tollive@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

